Hengrui partners X-Body to bring AMD antibody to China
This article was originally published in Scrip
Few Chinese pharmaceutical companies are capable of independently developing novel antibodies, which require costly equipment, skilled employees and investment in R&D. But Jiangsu Hengrui Medicine, a major Chinese firm based in Lianyungang, has decided to take the plunge through a new partnership with the US therapeutic antibody developer X-Body Biosciences, with an eye on the growing Chinese market for age-related macular degeneration (AMD).
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.